Abstract

C1-inhibitor (C1-INH) is an important regulator of the complement, coagulation, fibrinolytic and contact systems. The quantity of protease/C1-INH complexes in the blood is proportional to the level of the in vivo activation of these four cascade-like plasma enzyme systems. Parallel determination of C1-INH-containing activation complexes could be important to understand the regulatory role of C1-INH in diseases such as hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE). We developed in-house ELISAs to measure the concentration of complexes of C1-INH formed with active proteases: C1r, C1s, MASP-1, MASP-2, plasma kallikrein, factor XIIa, factor XIa, and thrombin, as well as to determine total and functionally active C1-INH. We measured the concentration of the complexes in EDTA plasma from 6 healthy controls, from 5 with type I and 5 with type II C1-INH-HAE patients during symptom-free periods and from five patients during HAE attacks. We also assessed the concentration of these complexes in blood samples taken from one C1-INH-HAE patient during the kinetic follow-up of a HAE attack. The overall pattern of complexed C1-INH was similar in controls and C1-INH-HAE patients. C1-INH formed the highest concentration complexes with C1r and C1s. We observed higher plasma kallikrein/C1-INH complex concentration in both type I and type II C1-INH-HAE, and higher concentration of MASP-1/C1-INH, and MASP-2/C1-INH complexes in type II C1-INH-HAE patients compared to healthy controls and type I patients. Interestingly, none of the C1-INH complex concentrations changed significantly during HAE attacks. During the kinetic follow-up of an HAE attack, the concentration of plasma kallikrein/C1-INH complex was elevated at the onset of the attack. In parallel, C1r, FXIIa and FXIa complexes of C1-INH also tended to be elevated, and the changes in the concentrations of the complexes followed rather rapid kinetics. Our results suggest that the complement classical pathway plays a critical role in the metabolism of C1-INH, however, in C1-INH-HAE, contact system activation is the most significant in this respect. Due to the fast changes in the concentration of complexes, high resolution kinetic follow-up studies are needed to clarify the precise molecular background of C1-INH-HAE pathogenesis.

Highlights

  • C1-esterase inhibitor (C1-INH) belongs to the superfamily of serine protease inhibitors

  • We explored and quantified the differences in the activation of the proteases regulated by C1-INH, which have been found between healthy individuals and C1-INH-Hereditary angioedema (HAE) patients with or without angioedematous symptoms

  • The detection limits of the total C1-INH concentration (C1-INHt) and the active C1-INH concentration (C1-INHa) ELISAs were calculated in relation to the corresponding total C1-INH concentrations we had measured in healthy individuals (Table 2)

Read more

Summary

Introduction

C1-esterase inhibitor (C1-INH) belongs to the superfamily of serine protease inhibitors. With its mean plasma concentration of 0.25 g/L (3.5 μmol/L) [1], it is among the most abundant protease inhibitors present in the systemic blood circulation It can inhibit a number of target proteases and, due to its multi-functional role, C1-INH is the key regulator of the complement and contact systems, and is involved in the control of blood coagulation and fibrinolysis [2]. The decline of the plasma level of active C1INH below a critical value [7, 8] is accompanied by the activation of the plasma enzyme systems regulated by this protein These processes lead to the production of mediators that enhance vascular permeability and, eventually, to angioedema [9]. The direct role of active MASP-1, generated during complement activation [11,12,13], as well as that of thrombin, released upon the activation of the coagulation system [14], have been implicated

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.